Idiopathic Pulmonary Fibrosis
AVLNAvalyn PharmaCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Nintedanib (AP02) (Antifibrotic Therapy) in Idiopathic Pulmonary Fibrosis. The expected timing is based on the latest available company guidance and may change.
06/03/26:- AURA Ph2 enrollment underway; topline data anticipated Late 2027. 08/12/26:- AURA Ph2 enrollment remains on track. Topline data are expected in Late 2027.
Verification
Confirm timing and program details against the company announcement or filing.